{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:05Z","timestamp":1790775485880,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11864-011-0165-1","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T10:52:53Z","timestamp":1317379973000},"page":"354-368","source":"Crossref","is-referenced-by-count":12,"title":["The 5q- Syndrome: Biology and Treatment"],"prefix":"10.1007","volume":"12","author":[{"given":"Eric","family":"Padron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"165_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","volume":"251","author":"H Berghe Van Den","year":"1974","unstructured":"Van Den Berghe H, Cassiman J-J, David G, Fryns J-P, Michaux J-L, Sokal G. Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature. 1974;251:437\u20138.","journal-title":"Nature"},{"key":"165_CR2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.V70.6.1705.1705","volume":"70","author":"SD Nimer","year":"1987","unstructured":"Nimer SD, Golde DW. The 5q- abnormality. Blood. 1987;70:1705\u201312.","journal-title":"Blood"},{"key":"165_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2141.2008.07447.x","volume":"144","author":"A Mohamedali","year":"2009","unstructured":"Mohamedali A, Mufti GJ. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol. 2009;144:157\u201368.","journal-title":"Br J Haematol"},{"key":"165_CR4","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/JCO.2005.03.6715","volume":"24","author":"SD Nimer","year":"2006","unstructured":"Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006;24:2576\u201382.","journal-title":"J Clin Oncol"},{"key":"165_CR5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2010.02.013","volume":"24","author":"RS Komrokji","year":"2010","unstructured":"Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010;24:377\u201388.","journal-title":"Hematol Oncol Clin North Am"},{"key":"165_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549\u201357.","journal-title":"N Engl J Med"},{"key":"165_CR7","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1002\/cncr.24575","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115:5202\u20139.","journal-title":"Cancer"},{"key":"165_CR8","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1073\/pnas.94.13.6948","volume":"94","author":"N Zhao","year":"1997","unstructured":"Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1\u20131.5\u00a0Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94:6948\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1098-2264(199807)22:3<251::AID-GCC11>3.0.CO;2-R","volume":"22","author":"RJ Jaju","year":"1998","unstructured":"Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 1998;22:251\u20136.","journal-title":"Genes Chromosomes Cancer"},{"key":"165_CR10","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1073\/pnas.90.12.5484","volume":"90","author":"MM Beau Le","year":"1993","unstructured":"Le Beau MM, Espinosa 3rd R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993;90:5484\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/geno.1994.1090","volume":"19","author":"J Boultwood","year":"1994","unstructured":"Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics. 1994;19:425\u201332.","journal-title":"Genomics"},{"key":"165_CR12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1126\/science.8438156","volume":"259","author":"CL Willman","year":"1993","unstructured":"Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 1993;259:968\u201371.","journal-title":"Science"},{"key":"165_CR13","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1182\/blood.V99.12.4638","volume":"99","author":"J Boultwood","year":"2002","unstructured":"Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99:4638\u201341.","journal-title":"Blood"},{"key":"165_CR14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2007.06833.x","volume":"139","author":"J Boultwood","year":"2007","unstructured":"Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol. 2007;139:578\u201389.","journal-title":"Br J Haematol"},{"key":"165_CR15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/leu.2010.31","volume":"24","author":"A Pellagatti","year":"2010","unstructured":"Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756\u201364.","journal-title":"Leukemia"},{"key":"165_CR16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm1512","volume":"13","author":"TX Liu","year":"2007","unstructured":"Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13:78\u201383.","journal-title":"Nat Med"},{"key":"165_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2005-12-4769","volume":"108","author":"A Pellagatti","year":"2006","unstructured":"Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108:337\u201345.","journal-title":"Blood"},{"key":"165_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","volume":"451","author":"BL Ebert","year":"2008","unstructured":"Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451:335\u20139.","journal-title":"Nature"},{"key":"165_CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01570781","volume":"12","author":"NN Nakamichi","year":"1986","unstructured":"Nakamichi NN, Kao FT, Wasmuth J, Roufa DJ. Ribosomal protein gene sequences map to human chromosomes 5, 8, and 17. Somat Cell Mol Genet. 1986;12:225\u201336.","journal-title":"Somat Cell Mol Genet"},{"key":"165_CR20","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1128\/MCB.6.8.2774","volume":"6","author":"DD Rhoads","year":"1986","unstructured":"Rhoads DD, Dixit A, Roufa DJ. Primary structure of human ribosomal protein S14 and the gene that encodes it. Mol Cell Biol. 1986;6:2774\u201383.","journal-title":"Mol Cell Biol"},{"key":"165_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01538680","volume":"8","author":"S Dana","year":"1982","unstructured":"Dana S, Wasmuth JJ. Linkage of the leuS, emtB, and chr genes on chromosome 5 in humans and expression of human genes encoding protein synthetic components in human\u2013Chinese hamster hybrids. Somatic Cell Genet. 1982;8:245\u201364.","journal-title":"Somatic Cell Genet"},{"key":"165_CR22","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/blood-2009-10-178129","volume":"115","author":"A Narla","year":"2010","unstructured":"Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115:3196\u2013205.","journal-title":"Blood"},{"key":"165_CR23","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood-2004-03-1089","volume":"105","author":"SE Craven","year":"2005","unstructured":"Craven SE, French D, Ye W, de Sauvage F, Rosenthal A. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood. 2005;105:3528\u201334.","journal-title":"Blood"},{"key":"165_CR24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/ng.188","volume":"40","author":"KA McGowan","year":"2008","unstructured":"McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40:963\u201370.","journal-title":"Nat Genet"},{"key":"165_CR25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/era.10.135","volume":"10","author":"C Heise","year":"2010","unstructured":"Heise C, Carter T, Schafer P, Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010;10:1663\u201372.","journal-title":"Expert Rev Anticancer Ther"},{"key":"165_CR26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","volume":"69","author":"J Momand","year":"1992","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237\u201345.","journal-title":"Cell"},{"key":"165_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/459046a","volume":"459","author":"S Ferreira-Cerca","year":"2009","unstructured":"Ferreira-Cerca S, Hurt E. Cell biology: arrest by ribosome. Nature. 2009;459:46\u20137.","journal-title":"Nature"},{"key":"165_CR28","unstructured":"Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010;16:59\u201366. This manuscript successfully crossed a powerful mouse model of the 5q- syndrome with a p-53 deficient mouse strain. This cross resulted in restoration of the hematopoetic progenitor defects seen in the 5q- model suggesting a critical P53 dependent mechanism."},{"key":"165_CR29","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","volume":"29","author":"M Jadersten","year":"2011","unstructured":"Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971\u20139.","journal-title":"J Clin Oncol"},{"key":"165_CR30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4161\/cc.9.5.11156","volume":"9","author":"DT Starczynowski","year":"2010","unstructured":"Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010;9:855\u20136.","journal-title":"Cell Cycle"},{"key":"165_CR31","doi-asserted-by":"crossref","unstructured":"Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49\u201358. This mansucript identified two miRs expressed within the common deleted region and their targets. They further showed that knocking these miRs down resulted in the partial recapitulation of the 5q- syndrome phenotype in a murine model.","DOI":"10.1038\/nm.2054"},{"key":"165_CR32","doi-asserted-by":"crossref","first-page":"e7102","DOI":"10.1371\/journal.pone.0007102","volume":"4","author":"AD DeWard","year":"2009","unstructured":"DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One. 2009;4:e7102.","journal-title":"PLoS One"},{"key":"165_CR33","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1038\/onc.2009.207","volume":"28","author":"KM Eisenmann","year":"2009","unstructured":"Eisenmann KM, Dykema KJ, Matheson SF, et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28:3429\u201341.","journal-title":"Oncogene"},{"key":"165_CR34","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1158\/0008-5472.CAN-07-1467","volume":"67","author":"J Peng","year":"2007","unstructured":"Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67:7565\u201371.","journal-title":"Cancer Res"},{"key":"165_CR35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L","volume":"72","author":"RP Huang","year":"1997","unstructured":"Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer. 1997;72:102\u20139.","journal-title":"Int J Cancer"},{"key":"165_CR36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0092-8674(88)90485-0","volume":"53","author":"VP Sukhatme","year":"1988","unstructured":"Sukhatme VP, Cao XM, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37\u201343.","journal-title":"Cell"},{"key":"165_CR37","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1073\/pnas.85.13.4691","volume":"85","author":"P Lemaire","year":"1988","unstructured":"Lemaire P, Revelant O, Bravo R, Charnay P. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc Natl Acad Sci U S A. 1988;85:4691\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR38","doi-asserted-by":"crossref","first-page":"11831","DOI":"10.1073\/pnas.93.21.11831","volume":"93","author":"C Liu","year":"1996","unstructured":"Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1996;93:11831\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR39","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1074\/jbc.274.7.4400","volume":"274","author":"C Liu","year":"1999","unstructured":"Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D. The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem. 1999;274:4400\u201311.","journal-title":"J Biol Chem"},{"key":"165_CR40","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1074\/jbc.M210279200","volume":"278","author":"T Virolle","year":"2003","unstructured":"Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem. 2003;278:11802\u201310.","journal-title":"J Biol Chem"},{"key":"165_CR41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2007-01-068809","volume":"110","author":"JM Joslin","year":"2007","unstructured":"Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110:719\u201326.","journal-title":"Blood"},{"key":"165_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0888-7543(88)90107-3","volume":"2","author":"A Swaroop","year":"1988","unstructured":"Swaroop A, Hogan BL, Francke U. Molecular analysis of the cDNA for human SPARC\/osteonectin\/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 1988;2:37\u201347.","journal-title":"Genomics"},{"key":"165_CR43","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1073\/pnas.91.8.3448","volume":"91","author":"SE Goldblum","year":"1994","unstructured":"Goldblum SE, Ding X, Funk SE, Sage EH. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci U S A. 1994;91:3448\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR44","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","volume":"104","author":"A Pellagatti","year":"2007","unstructured":"Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104:11406\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR45","unstructured":"Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-hodgkin lymphoma cells are associated with increased SPARC expression. Blood (ASH Annual Meeting Abstracts) 2008;112:2612-."},{"key":"165_CR46","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/sj.leu.2404852","volume":"21","author":"S Lehmann","year":"2007","unstructured":"Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21:1931\u20136.","journal-title":"Leukemia"},{"key":"165_CR47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/1096-8652(200008)64:4<324::AID-AJH19>3.0.CO;2-6","volume":"64","author":"C Fidler","year":"2000","unstructured":"Fidler C, Strickson A, Boultwood J, Waincoat JS. Mutation analysis of the SPARC gene in the 5q-syndrome. Am J Hematol. 2000;64:324.","journal-title":"Am J Hematol"},{"key":"165_CR48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1097-2765(00)80447-5","volume":"5","author":"S Pokutta","year":"2000","unstructured":"Pokutta S, Weis WI. Structure of the dimerization and beta-catenin-binding region of alpha-catenin. Mol Cell. 2000;5:533\u201343.","journal-title":"Mol Cell"},{"key":"165_CR49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0092-8674(01)00246-X","volume":"104","author":"V Vasioukhin","year":"2001","unstructured":"Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell. 2001;104:605\u201317.","journal-title":"Cell"},{"key":"165_CR50","doi-asserted-by":"crossref","first-page":"18199","DOI":"10.1073\/pnas.0705730104","volume":"104","author":"H Shibata","year":"2007","unstructured":"Shibata H, Takano H, Ito M, et al. Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A. 2007;104:18199\u2013204.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"165_CR51","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/MCB.01904-05","volume":"26","author":"AM Gil-Bernabe","year":"2006","unstructured":"Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol. 2006;26:4017\u201327.","journal-title":"Mol Cell Biol"},{"key":"165_CR52","doi-asserted-by":"crossref","unstructured":"Jones TA, Barker HM, da Cruz e Silva EF, et al. Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-->q31 and 8p12-->p11.2, respectively. Cytogenet Cell Genet 1993;63:35\u201341.","DOI":"10.1159\/000133497"},{"key":"165_CR53","doi-asserted-by":"crossref","unstructured":"Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009;106:12974\u20139. This manuscript identifies a link between the common deleted region and sensitivity to lenalidomide in low risk MDS with a del(5q) abnormality.","DOI":"10.1073\/pnas.0811267106"},{"key":"165_CR54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0888-7543(92)90190-4","volume":"13","author":"H Sartor","year":"1992","unstructured":"Sartor H, Ehlert F, Grzeschik KH, Muller R, Adolph S. Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. Genomics. 1992;13:911\u20132.","journal-title":"Genomics"},{"key":"165_CR55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/351242a0","volume":"351","author":"U Strausfeld","year":"1991","unstructured":"Strausfeld U, Labbe JC, Fesquet D, et al. Dephosphorylation and activation of a p34cdc2\/cyclin B complex in vitro by human CDC25 protein. Nature. 1991;351:242\u20135.","journal-title":"Nature"},{"key":"165_CR56","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.1703321","volume":"250","author":"KL Gould","year":"1990","unstructured":"Gould KL, Moreno S, Tonks NK, Nurse P. Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase. Science. 1990;250:1573\u20136.","journal-title":"Science"},{"key":"165_CR57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/35075107","volume":"411","author":"DV Bulavin","year":"2001","unstructured":"Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2\/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411:102\u20137.","journal-title":"Nature"},{"key":"165_CR58","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/leu.2009.53","volume":"23","author":"BL Ebert","year":"2009","unstructured":"Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23:1252\u20136.","journal-title":"Leukemia"},{"key":"165_CR59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210\u20136.","journal-title":"Blood"},{"issue":"Suppl","key":"165_CR60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/107327480601304s02","volume":"13","author":"AF List","year":"2006","unstructured":"List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006;13(Suppl):4\u201311.","journal-title":"Cancer Control"},{"key":"165_CR61","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456\u201365.","journal-title":"N Engl J Med"},{"key":"165_CR62","unstructured":"List A, Wride K, Knight R. Transfusion burden, disease duration and age identify non-deletion 5q MDS patients highly responsive to lenalidomide treatment. European Hematology Association, 13th congress 2008."},{"key":"165_CR63","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","volume":"26","author":"MA Sekeres","year":"2008","unstructured":"Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943\u20139.","journal-title":"J Clin Oncol"},{"key":"165_CR64","doi-asserted-by":"crossref","unstructured":"Fenaux P, Giagounidis A, Selleslag DL, et al. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-\/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. J Clin Oncol (Meeting Abstracts) 2010;28:6598-.","DOI":"10.1200\/jco.2010.28.15_suppl.6598"},{"key":"165_CR65","doi-asserted-by":"crossref","unstructured":"Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011. This is a large phase 3 clinical trial preformed in Europe confirming the superior efficacy and acceptable safety of lenalidomide in low-risk transfusion dependent MDS patients with a del(5q) abnormality.","DOI":"10.1182\/blood-2011-01-330126"},{"key":"165_CR66","unstructured":"Ades L, Lebras F, Sebert M, et al. Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM). ASH Annual Meeting Abstracts 2010;116:976-."},{"key":"165_CR67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314\u201322.","journal-title":"Nat Rev Cancer"},{"key":"165_CR68","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380\u20136.","journal-title":"J Immunol"},{"key":"165_CR69","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","volume":"69","author":"L Escoubet-Lozach","year":"2009","unstructured":"Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347\u201356.","journal-title":"Cancer Res"},{"key":"165_CR70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","volume":"9","author":"GW Muller","year":"1999","unstructured":"Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9:1625\u201330.","journal-title":"Bioorg Med Chem Lett"},{"key":"165_CR71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","volume":"67","author":"D Verhelle","year":"2007","unstructured":"Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746\u201355.","journal-title":"Cancer Res"},{"key":"165_CR72","doi-asserted-by":"crossref","unstructured":"List AF, Rocha K, Zhang L, et al. Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression. ASH Annual Meeting Abstracts 2009;114:292-.","DOI":"10.1182\/blood.V114.22.292.292"},{"key":"165_CR73","doi-asserted-by":"crossref","unstructured":"Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010;363:1025\u201337. Lenalidomide responding patients with the 5q- syndrome are not cured from their disease. Relapse is nearly universal after some time. This manuscript provides biological evidence of this by showing that, even in responding patient, there exists a lenalidomide non-responsive stem cell compartment","DOI":"10.1056\/NEJMoa0912228"},{"key":"165_CR74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","volume":"15","author":"LR Coulthard","year":"2009","unstructured":"Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15:369\u201379.","journal-title":"Trends Mol Med"},{"key":"165_CR75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","volume":"116","author":"P Musto","year":"2010","unstructured":"Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer. 2010;116:1485\u201394.","journal-title":"Cancer"},{"key":"165_CR76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2009.09.024","volume":"16","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16:369\u201377.","journal-title":"Cancer Cell"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-011-0165-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0165-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T05:06:15Z","timestamp":1686373575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-011-0165-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1007\/s11864-011-0165-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}